

## Supplementary material

**Supplementary Table 1** Impact of multidisciplinary team discussion on patient management: cystic vs. solid lesions

Management approach	Management of cystic lesions before MDT	Management of cystic lesions after MDT	P-value	Management of solid lesions before MDT	Management of solid lesions after MDT	P-value
None, %	43.8	5.9	<0.001	26.7	2.1	<0.001
Chemotherapy, %	0.5	6.5		24.6	53.7	
Surgery, %	4.3	8.1		12.2	12.5	
Imaging follow-up, %	28.6	48.1		5	7.7	
Clinical follow-up, %	14.1	21.1		2.1	7.7	
Endoscopy, %	8.6	1.1		27.6	2.7	
Radiotherapy, %	0	0.5		1.2	5.6	
Palliative care, %	0	1.1		0	2.7	
Other, %	0	7.6		0.6	5.3	

MDT, multidisciplinary team

**Supplementary Table 2** Impact of multidisciplinary team discussion on patient diagnosis: cystic vs. solid lesions

Diagnosis	Diagnosis of cystic lesions before MDT	Diagnosis of cystic lesions after MDT	P-value	Diagnosis of solid lesions before MDT	Diagnosis of solid lesions after MDT	P-value
Adenocarcinoma, %	0	7.6	NS	74.2	74.8	NS
IPMN, %	7.6	50.3		1.8	2.4	
NET, %	1.6	3.8		11.6	10.1	
Serous cystadenoma, %	11.4	16.2		0.6	0.6	
Mucinous cystadenoma, %	9.2	6.5		0.3	0	
Cholangiocarcinoma, %	0	0		2.7	2.7	
Cystic dystrophy of the duodenal wall, %	2.2	2.2		0	0	
Ampulloma %	0	0		2.1	1.5	
Unknown, %	15.1	2.2		1.2	0	
Other, %	5.4	11.4		5.6	8	

MDT, multidisciplinary team; IPMN, intraductal papillary mucinous neoplasm; NET, neuroendocrine tumor; NS, non significant